Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 3

ash.confex.com

Oral and Poster Abstracts Oral 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Evolution of Immunotherapeutic Regimens in B-cell Lymphomas Biological, Lymphoid Leukemias, Cytokine Release Syndrome, Bispecific Antibody Therapy, Lymphomas, Non-Hodgkin Lymphoma, Diseases, Indolent Lymphoma, Therapies, Immunotherapy, Lymphoid...

  • 123456 Profile photo of Madelyn

    Glofitamab with obinutuzumab had a ORR of 100% and a CMR rate of 73.7% in relapsed/refractory follicular lymphoma. 79% had CRS, with no grade 3 CRS events.